Solventum (NYSE:SOLV) announced a strategic partnership with SprintRay to deliver disruptive 3D printing for dental ...

Solventum (NYSE:SOLV – Get Free Report) is one of 238 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will ...

Solventum expects 2028 operating margins of 23%-25% and 10% EPS CAGR. Q4 adjusted EPS of $1.41 beat the consensus of $1.32 on $2.07 billion in sales. Feel unsure about the market’s next move ...

ST. PAUL, Minn., March 20, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today hosts its 2025 Investor Day and will outline strategic priorities for the Company, its business segments, and its long ...

Solventum presently has a consensus price target of $79.86, suggesting a potential upside of 7.46%. As a group, “Surgical & medical instruments” companies have a potential upside of 31.83%.

On Thursday, Solventum (NYSE:SOLV) hosted its 2025 Investor Day, during which it outlined its strategic priorities, its business segments, and its long-range plan (LRP) to drive growth and value ...

Adjusted free cash flow significantly declined to $92 million from $459 million in Q4 2023. Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments ...

What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...

Diversified healthcare company Solventum (NYSE:SOLV) reported fourth-quarter 2024 earnings on Thursday, Feb. 27, that topped analysts' consensus estimates. Adjusted EPS for the quarter came in at ...

Piper Sandler analyst Jason Bednar maintained a Hold rating on Solventum Corporation (SOLV – Research Report) today and set a price target of $84.00. The company’s shares closed yesterday at ...